benralizumab

03/01/2023 - "Benralizumab is highly effective in many, but not all, patients with severe asthma. "
09/01/2020 - "In conclusion, our results suggest that via its anti-eosinophil actions benralizumab improved airflow limitation, lung hyperinflation, and respiratory symptoms, as well as lowered asthma exacerbation rate and abrogated OCS consumption in most patients."
06/28/2023 - "Benralizumab treatment resulted in a marked improvement in asthma control, suppressed blood eosinophil levels and reduction in the number of exacerbations in the subgroup of patients with severe eosinophilic asthma and nasal polyposis. "
01/01/2023 - "Benralizumab induction resulted in a marked decrease in blood and sputum eosinophil levels and a significant improvement in asthma symptoms, quality of life scores, FEV1, and exacerbation frequency. "
12/01/2022 - "This met the minimum clinically important difference (MCID) for the broader St. George's Respiratory Questionnaire (SGRQ; 4-point change) for benralizumab only, but the improvement in the ACQ and Asthma Quality of Life Questionnaire (AQLQ), which focus on asthma symptoms, fell short of the MCID (0.5 point change for both ACQ and AQLQ) for all of the interventions. "

09/01/2023 - "After benralizumab administration he demonstrated improvement in his left ventricular ejection fraction, normalization of his right ventricular function, and improvement in symptoms with resolution of his hypereosinophilia. "
05/01/2021 - "A treatment trial with benralizumab was more successful and led to suppression of airway eosinophilia. "
03/06/2021 - "Further clinical studies are warranted to determine whether benralizumab or other drugs targeted against IL-5/IL-5R may be useful in managing multiple conditions associated with eosinophilia."
01/01/2022 - "Benralizumab treatment completely depleted blood and GI tissue eosinophilia in patients with eosinophilic GI disorders, but clinical response, while encouraging, was heterogeneous. "
01/01/2021 - "Benralizumab was prescribed with complete resolution of eosinophilia and lung infiltrates with no adverse effect."

08/01/2023 - "Benralizumab: A novel treatment for the cutaneous features of paediatric eosinophilic granulomatosis with polyangiitis (pEGPA)."
05/15/2023 - "Long-term Safety and Efficacy of Benralizumab for Eosinophilic Granulomatosis with Polyangiitis Complicated with Severe Neuropathy."
01/01/2022 - "Benralizumab monotherapy was insufficient to induce remission in patients with active eosinophilic granulomatosis with polyangiitis."
01/01/2022 - "Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis."
12/01/2023 - "Reports on the use of benralizumab for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) are limited to case reports and small case series. "

01/01/2019 - "In this small phase 2 trial, patients with PDGFRA-negative hypereosinophilic syndrome who received benralizumab for 12 weeks had lower absolute eosinophil counts than those who received placebo. "
01/01/2021 - "Benralizumab in Severe and Refractory PDGFRA-Negative Hypereosinophilic Syndrome."
01/01/2021 - "Successful treatment of idiopathic hypereosinophilic syndrome with benralizumab in a pediatric patient."
01/01/2019 - "Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome."
01/01/2022 - "Although benralizumab proved clinically efficacious in clinical trials for patients with severe asthma and hypereosinophilic syndrome, in-depth characterisation of its anti-eosinophilic mechanisms of action remains elusive. "

12/01/2020 - "The proportion of patients who achieved successful switching to benralizumab was higher in patients with eosinophilic chronic rhinosinusitis (ECRS) than in those without (76.9 vs. 20.0%; p = 0.025). "
01/01/2022 - "Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial."
01/01/2021 - "Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial."
01/01/2022 - "The efficacy and safety of benralizumab in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) remain unresolved, and relevant meta-analyses are lacking. "
01/01/2020 - "Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma."